• English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
April 22nd - The Middle East conflict has led to rising global aviation fuel costs, putting pressure on airlines. According to data from aviation analytics firm Rescommend, 19 of the worlds 20 largest airlines plan to cut flights in May. Rescommends analysis shows that global airlines planned capacity in May is down by about 3% compared to early March. The agency previously predicted that global capacity would grow by 4% to 6% for the whole year, but now judges that in some cases, full-year capacity may even decline, by as much as 3%. On Tuesday, local time, Lufthansa announced that it would cancel approximately 20,000 flights between May and October. Furthermore, Lufthansa stated that it would suspend some low-profit routes from Munich and Frankfurt from now until around mid-October. Lufthansa stated that aviation fuel prices have doubled since the outbreak of the Middle East conflict. The latest measures may help it save approximately 40,000 tons of aviation fuel.Sources say the Sizlan oil refinery in Russia has halted oil processing following the drone attack on April 18.Tesla (TSLA.O) executive: Model YL deliveries will begin in India this quarter.April 22 – It was learned today that during a recent on-site inspection of drugs overseas, the National Medical Products Administration (NMPA) discovered that two Indian companies had implemented changes to their colchicine raw material production processes without obtaining approval or filing as required by relevant Chinese laws and regulations, which does not comply with the requirements of my countrys Good Manufacturing Practice (GMP) for pharmaceuticals and its appendices. Based on the Drug Administration Law of the Peoples Republic of China and other regulations, the NMPA has decided to suspend the import of colchicine raw materials from these two companies, effective immediately. These raw materials are prohibited from sale in my country and from use in pharmaceutical preparations. Drugs already produced using these raw materials will not be released. For drugs already marketed, the NMPA requires marketing authorization holders to immediately conduct investigations and assessments, and take necessary risk control measures based on the assessment results.On April 22, Foreign Ministry Spokesperson Guo Jiakun hosted a regular press conference. In recent years, China has made continuous breakthroughs in emerging fields such as artificial intelligence, quantum technology, and manned spaceflight, and the popularity of "Made in China" is catching up with that of "Created in China." However, some countries still question whether China has infringed on intellectual property rights and "stole" cutting-edge technologies in key areas, and have issued various bans against China on this basis. What is the spokespersons comment on this? Guo Jiakun stated that protecting intellectual property rights is protecting innovation and safeguarding high-quality development. China has become a major intellectual property power in the world, ranking first in international patent applications for many years. China is not only the "worlds factory" but is also growing into a "global innovation laboratory." The so-called "stealing" of intellectual property rights is completely unfounded. Chinas development relies on its own unremitting efforts and also benefits from mutually beneficial international cooperation.

Rising Rates and Volatility are Features, Not Bugs: Top Trade Opportunities

Cameron Murphy

Apr 19, 2022 10:37


微信截图_20220414102141.png


The S&P 500 outpaced the Nasdaq 100 in the first few months of 2022, EUR/USD rates fell below 1.1000, and the US Treasury yield curve (2s10s) went into inversion territory, as predicted in the 1Q'22 Top Trading Opportunities. While one of the primary causes – Russia's invasion of Ukraine and the accompanying crisis in commodities markets – wasn't on our metaphorical bingo card, the other price drivers were central banks' rapid interest rate hikes and the end of fiscal stimulus.


The primary price drivers from 1Q'22 are likely to continue into 2Q'22. The Federal Reserve is increasing interest rates more aggressively, following a chorus of other major central banks in reversing monetary easing. When it comes to greater fiscal stimulus, governments are "tapped out." Although the COVID-19 outbreak is waning, lockdowns are still occurring on a regular basis (e.g. China). Even if Russia concludes its conflict with Ukraine, the consequences for supply networks would last for months.


Concerns over decreasing economic growth in developed nations, as well as greater volatility in 2Q'22, imply that more volatility is on the way. Risk appetite will fluctuate throughout the year before becoming more positive later in the year.


As 2Q'22 begins, the ratio has been steadily retracing from a high of 1.31 before rising. However, the possible double bottom that formed against the 1Q'21 and 4Q'21 lows remains legitimate, indicating that the transition from growth to value stocks is still in its early stages. The long S&P 500/short Nasdaq 100 strategy remains popular, with an entry around 1.22 and a climb to 1.35 expected in the following months.


The argument behind predicting a US Treasury yield curve inversion is simple: when the Fed decreases stimulus, the short-end of the yield curve tends to see higher rates, while the long-end tends to see lower rates as growth and inflation expectations – intrinsically incorporated in the long-end – fall down.


In the 2s10s spread, a further flattening of the US yield curve is still projected, heightening recession worries for late-2022/early-2023. Inversions of the yield curve, on the other hand, seldom endure long, therefore this viewpoint has a short shelf life (also, after yield curves invert, stocks tend to bottom).


We continue to believe that the gap between the Federal Reserve and the European Central Bank will widen in the coming months, and that the divergence between US and Eurozone inflation rates will weaken the EUR/USD exchange rate even more. The ECB may hike rates later this year, but the Fed may have already lifted rates by 100 to 150 basis points by that time. Early in 2Q22, EUR/USD rates are likely to return to the 1.0806 low from 1Q22, followed by a return to the 1.0636 low from 2020. (coinciding with the DXY Index move above 101.00 before topping).